| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| Cost of Revenue | $0 | — | -100.0% |
| R&D Expense | $17.2M | — | +96.1% |
| SG&A Expense | $6.3M | — | -50.9% |
| Operating Income | -$23.5M | — | -54.6% |
| Pre-tax Income | -$22.2M | — | -130.4% |
| Income Tax | $0 | — | — |
| Net Income | -$22.2M | — | -130.4% |
| EPS (Basic) | -$0.32 | — | -117.4% |
| EPS (Diluted) | -$0.32 | — | -117.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $34.8M | -7.4% | -84.7% |
| Short-term Investments | $88.3M | -18.4% | +2426.6% |
| Current Assets | $125.5M | -15.7% | -46.0% |
| Total Assets | $127.2M | -15.6% | -45.6% |
| Current Liabilities | $11.1M | -23.9% | -9.9% |
| Total Liabilities | $11.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$22.2M | — | -87.2% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $19.4M | — | -83.2% |
| Financing Cash Flow | $0 | — | -100.0% |
| Free Cash Flow | -$22.2M | — | -78.9% |
| -9.9% |
| Stockholders' Equity | $116.2M | -14.8% | -47.6% |